Dr. Choueiri on the Research With Immunotherapy in RCC

Toni Choueiri, MD
Published: Friday, Oct 13, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

There is ongoing research investigating patients who progressed on prior immunotherapy regimens and received cabozantinib (Cabometyx). Those patients experienced a beneficial response with cabozantinib compared to everolimus, states Choueiri.

SELECTED
LANGUAGE


Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

There is ongoing research investigating patients who progressed on prior immunotherapy regimens and received cabozantinib (Cabometyx). Those patients experienced a beneficial response with cabozantinib compared to everolimus, states Choueiri.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x